Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
verubulin + temozolomide
- Development stage
- Unknown
- Lead developer
- Myrexis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Verubulin + temozolomide** is a combination regimen under investigation for the treatment of newly diagnosed glioblastoma multiforme (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that has demonstrated high brain penetration and disrupts tumor vasculature by inhibiting microtubule polymerization. Temozolomide is an alkylating agent that methylates DNA at the O6 and N7 positions of guanine, leading to apoptosis in tumor cells, especially those with impaired DNA repair. The combination aims to leverage the synergistic effects of two distinct mechanisms—microtubule disruption and DNA alkylation—to enhance tumor cell death and overcome resistance to temozolomide. This combination is currently being evaluated in clinical trials for glioblastoma where both drugs are administered together with radiation therapy[3][4][5].
- Brand names
- Temomedac
- Other names
- verubulin + temozolomide
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on verubulin + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on verubulin + temozolomide.